MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-19-2025
OpGen Interest Expense 2011-2026 | OPGN
Interest expense is the amount of interest a company is obligated to pay to creditors for using debt financing (bank loans, bonds, leasing, etc.) during the reporting period.Includes:
- Interest on bank loans
- Interest on corporate bonds
- Interest on leases
- Interest on credit lines and overdrafts
High interest expenses indicate a high debt burden — the company may be vulnerable to rising rates or declining revenue.
Low interest expenses with high profits are a sign of financial stability.
Annual Interest Expense OpGen
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 7.56 K | 1.84 M | 3.26 M | 4.8 M | 3.4 M | 188 K | 191 K | 234 K | 143 K | 1.8 M | 111 K | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 4.8 M | 7.56 K | 1.45 M |
Quarterly Interest Expense OpGen
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 3.92 K | 1.62 K | 3.24 K | - | 3.24 K | 1.08 K | - | - | 397 K | 684 K | 617 K | - | 569 K | 780 K | 1.27 M | - | 1.22 M | 1.2 M | 1.16 M | - | 1.18 M | 1.04 M | 38.3 K | - | 49.1 K | 37.1 K | 56.4 K | - | 28.1 K | 54.5 K | 57.8 K | - | 90.3 K | 53.8 K | 29.8 K | - | 41.4 K | 26.6 K | 41.7 K | - | 17.5 K | 1.63 M | 96.4 K | - | 32.3 K | 6.94 K | 8.2 K | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 1.63 M | 1.08 K | 358 K |
Interest Expense of other stocks in the Diagnostics research industry
| Issuer | Interest Expense | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Akumin
AKU
|
118 M | - | -17.87 % | $ 25.9 M |  Canada |
|
Centogene N.V.
CNTG
|
8.42 M | - | -6.23 % | $ 30.6 M |  Germany |
 |
Agilent Technologies
A
|
81 M | $ 111.3 | -3.12 % | $ 33.8 B |  USA |
 |
Castle Biosciences
CSTL
|
1 K | $ 24.24 | -1.86 % | $ 673 M | USA |
 |
Accelerate Diagnostics
AXDX
|
235 K | - | -61.36 % | $ 2.46 M | USA |
 |
Aspira Women's Health
AWH
|
1.81 M | - | -6.19 % | $ 10.5 M | USA |
 |
Biocept
BIOC
|
316 K | - | -13.05 % | $ 7.29 M | USA |
 |
Chembio Diagnostics
CEMI
|
2.94 K | - | 0.22 % | $ 16.8 M | USA |
 |
Neogen Corporation
NEOG
|
38.1 M | $ 9.01 | -3.53 % | $ 1.95 B | USA |
 |
Check-Cap Ltd.
CHEK
|
13 K | - | - | $ 9.42 M |  Israel |
 |
Koninklijke Philips N.V.
PHG
|
288 M | $ 25.58 | -5.68 % | $ 20 B |  Niderland |
 |
Co-Diagnostics
CODX
|
106 K | $ 1.53 | -6.13 % | $ 2.04 M | USA |
 |
Personalis
PSNL
|
24 K | $ 5.04 | -8.36 % | $ 299 M | USA |
 |
CareDx, Inc
CDNA
|
524 K | $ 20.8 | -5.07 % | $ 1.11 B | USA |
 |
DermTech
DMTK
|
-355 K | - | -11.32 % | $ 2.94 M | USA |
 |
Enzo Biochem
ENZ
|
494 K | - | -8.98 % | $ 14.8 K | USA |
 |
Exact Sciences Corporation
EXAS
|
18.6 M | - | - | $ 19.8 B | USA |
 |
Fulgent Genetics
FLGT
|
561 K | $ 14.8 | -3.27 % | $ 447 M | USA |
 |
Illumina
ILMN
|
-292 M | $ 120.37 | -5.16 % | $ 19.1 B | USA |
 |
Global Cord Blood Corporation
CO
|
6.27 M | - | - | $ 399 M |  China |
 |
Genetic Technologies Limited
GENE
|
15.2 K | - | - | $ 7.1 B |  Australia |
 |
Charles River Laboratories International
CRL
|
-22.6 M | $ 163.84 | -1.77 % | $ 8.12 B | USA |
 |
Trinity Biotech plc
TRIB
|
6.75 M | $ 0.6 | -2.07 % | $ 61.9 M |  Irlanda |
 |
HTG Molecular Diagnostics
HTGM
|
857 K | - | -20.0 % | $ 1.06 M | USA |
 |
Guardant Health
GH
|
-10.5 M | $ 83.41 | 0.35 % | $ 10.5 B | USA |
 |
Twist Bioscience Corporation
TWST
|
-903 K | $ 56.7 | -4.14 % | $ 3.39 B | USA |
 |
Lantheus Holdings
LNTH
|
31.3 M | $ 81.17 | -2.85 % | $ 5.48 B | USA |
 |
Heska Corporation
HSKA
|
4.19 M | - | - | $ 1.31 B | USA |
 |
Interpace Biosciences
IDXG
|
-252 K | $ 1.99 | 2.9 % | $ 8.8 M | USA |
 |
Senseonics Holdings
SENS
|
-23 K | $ 6.43 | -10.52 % | $ 268 M | USA |
 |
QIAGEN N.V.
QGEN
|
-6.65 M | - | - | $ 10.6 B | Niderland |
 |
Medpace Holdings
MEDP
|
-5.34 M | $ 413.59 | 0.93 % | $ 11.9 B | USA |
 |
Biomerica
BMRA
|
367 | $ 2.16 | -1.22 % | $ 4.96 M | USA |
 |
Motus GI Holdings
MOTS
|
211 | - | -34.28 % | $ 263 K | Israel |
 |
ICON Public Limited Company
ICLR
|
337 M | $ 116.17 | 13.35 % | $ 9.58 B | Irlanda |
 |
Laboratory Corporation of America Holdings
LH
|
224 M | $ 257.14 | -0.94 % | $ 21.4 B | USA |
 |
NeoGenomics
NEO
|
296 K | $ 8.96 | -0.67 % | $ 1.15 B | USA |
 |
Celcuity
CELC
|
2.11 M | $ 119.0 | -0.89 % | $ 5.56 B | USA |
 |
National Research Corporation
NRC
|
-95 K | $ 16.54 | -1.78 % | $ 370 M | USA |
 |
Myriad Genetics
MYGN
|
800 K | $ 4.68 | -3.31 % | $ 433 M | USA |
 |
Natera
NTRA
|
9.32 M | $ 194.75 | -2.71 % | $ 19.2 B | USA |
 |
Quest Diagnostics Incorporated
DGX
|
26 M | $ 189.32 | -2.94 % | $ 21 B | USA |
 |
Invitae Corporation
NVTA
|
56.7 M | - | - | $ 21.2 M | USA |
 |
Burning Rock Biotech Limited
BNR
|
1.54 M | $ 16.24 | -2.46 % | $ 175 M | China |
 |
Organovo Holdings
ONVO
|
6 K | - | -2.3 % | $ 19.4 M | USA |